Pachankis, J., Chiaramonte, D., Scheer, J. R., Ankrum, H., Eisenstadt, B., Hobbs, R., Baldwin, H., Kidd, J. D., Witkiewitz, K., Esserman, D. A., Plourde, K., Drabble, L., & Hughes, T. (2025). Randomised controlled trial of LGBTQ-affirmative cognitive-behavioural therapy for sexual minority women’s minority stress, mental health and hazardous drinking: Project EQuIP protocol. BMJ Open, 15(3), e086738. https://doi.org/10.1136/bmjopen-2024-086738

Becker, T. D., Olfson, M., Menzi, P. J., Levin, F. R., Hasin, D. S., Nuckolls, C., & Sultan, R. S. (2025). Cannabis Access by Retailer Type in New York. Pediatrics, 155(3). https://doi.org/10.1542/peds.2024-068669

Hernández, M., Levin, F. R., & Campbell, A. N. C. (2025). ADHD and Alcohol Use Disorder: Optimizing Screening and Treatment in Co-occurring Conditions. CNS Drugs. https://doi.org/10.1007/s40263-025-01168-6

Lawn, W., Hao, X., Konova, A. B., Haney, M., Cooper, Z. D., Van Dam, N., Glimcher, P., & Bedi, G. (2025). Value signals guiding choices for cannabis versus non-drug rewards in people who use cannabis near-daily. Psychopharmacology. https://doi.org/10.1007/s00213-025-06746-6

Shulman, M., Choo, T.-H., Ohrtman, K., Pavlicova, M., Rotrosen, J., & Nunes, E. V. (2025). Effects of randomization to buprenorphine or naltrexone for OUD on cannabis use outcomes: A secondary analysis of the X:BOT trial. Drug and Alcohol Dependence, 268, 112550. https://doi.org/10.1016/j.drugalcdep.2025.112550

Shulman, M., Meyers-Ohki, S., Novo, P., Provost, S., Ohrtman, K., Van Veldhuisen, P., Oden, N., Otterstatter, M., Bailey, G. L., Liu, D., Rotrosen, J., Weiss, R. D., & Nunes, E. V. (2025). Optimizing retention strategies for opioid use disorder pharmacotherapy: The retention phase of the CTN-0100 trial (RDD). Contemporary Clinical Trials, 150, 107816. https://doi.org/10.1016/j.cct.2025.107816

Xu, K. Y., Berkel, T. D. M., Martin, C. E., Jones, H. E., Carter, E. B., Kelly, J. C., Mintz, C. M., Levin, F. R., & Grucza, R. A. (2024). Prescription psychostimulant use, admissions and treatment initiation and retention in pregnant people with opioid use disorder. Nature Mental Health, 2(7), 801–808. https://doi.org/10.1038/s44220-024-00270-w

Brynte, C., Schellekens, A., Barta, C., Begeman, A. H. A., Crunelle, C. L., Daigre, C., Demetrovics, Z., Dom, G., Grau-López, L., Hernandez, M., Icick, R., Johnson, B., Kapitány-Fövény, M., Kernebeek, M. van, Konstenius, M., Levin, F. R., Luderer, M., Matthys, F., Moggi, F., … Franck, J. (2024). Treatments and Treatment Predictors in Patients With Substance Use Disorders and Comorbid Attention-Deficit/Hyperactivity Disorder. The Journal of Clinical Psychiatry, 86(1). https://doi.org/10.4088/jcp.24m15494

Arout, C. A., Harris, H. M., Wilson, N. M., Mastropietro, K. F., Bozorgi, A. M., Fazilov, G., Tempero, J., Walker, M., & Haney, M. (2024). A Preliminary Pharmacokinetic Comparison of Δ-9 Tetrahydrocannabinol and Cannabidiol Extract Versus Oromucosal Spray in Healthy Men and Women. Cannabis and Cannabinoid Research. https://doi.org/10.1089/can.2023.0249

Peterson, S., Nunes, E. V., Lofwall, M. R., Walsh, S. L., & Tiberg, F. (2024). Exploring Opioid Use Disorder Outcomes by Quantitative Urinalysis: Post Hoc Analysis of a Phase 3 Randomized Clinical Trial. Journal of Addiction Medicine. https://doi.org/10.1097/adm.0000000000001405

Chalmé, R. L., Rubin, E., Evans, S. M., Haney, M., & Foltin, R. W. (2025). Venlafaxine treatment is associated with improved mood, but not decreased cocaine self-administration, in depressed people who use cocaine. Pharmacology Biochemistry and Behavior, 247, 173918. https://doi.org/10.1016/j.pbb.2024.173918

Balise, R. R., Hu, M.-C., Calderon, A. R., Odom, G. J., Brandt, L., Luo, S. X., & Feaster, D. J. (2024). Data cleaning and harmonization of clinical trial data: Medication-assisted treatment for opioid use disorder. PLOS ONE, 19(11), e0312695. https://doi.org/10.1371/journal.pone.0312695

Goddard-Eckrich, D., Grealis, K., El-Bassel, N., Lounsbury, D. W., Dsouza, N., Bhuiyan, J., Cervantes, M., Angerame, A., Feaster, D. J., Kim, E., Huang, T. T. K., Sabounchi, N. S., Gilbert, L., Levin, F. R., Edwards, K., Gatanaga, O. S., McCrimmon, T., David, J. L., Hunt, T., … Balise, R. (2025). Development of a brief stigma and perceptions questionnaire for pharmacists: An exploratory factor analysis approach in New York state counties enrolled in the healing communities study. Journal of Substance Use and Addiction Treatment, 169, 209566. https://doi.org/10.1016/j.josat.2024.209566

Luba, R., Castillo, F., Jones, J., Zammit, G., & Comer, S. D. (2023). Objective and self-reported sleep outcomes in people with comorbid alcohol and opioid use disorder: examining the role of gabapentin. Journal of Substance Use, 29(6), 1094–1099. https://doi.org/10.1080/14659891.2023.2248258

Elkington, K. S., Ryan, M. E., Basaraba, C., Dambreville, R., Alschuler, D., Wall, M. M., Garcia, A., Christofferson, M., Andrews, H. F., & Nunes, E. V. (2024). Examining the Impact of the Innovative Opioid Court Model on Treatment Access and Court Outcomes for Court Participants. Journal of Addiction Medicine, 18(6), 635–642. https://doi.org/10.1097/adm.0000000000001330

Baron, S. W., Wai, J. M., Aloezos, C., Cregin, R., Ceresnak, J., Dekhtyar, J., & Southern, W. N. (2024). Improving thiamine prescribing in alcohol use disorder using electronic decision support in a large urban academic medical center: A pre-post intervention study. Journal of Substance Use and Addiction Treatment, 166, 209485. https://doi.org/10.1016/j.josat.2024.209485

Imperio, C. G., Levin, F. R., & Martinez, D. (2024). The Neurocircuitry of Substance Use Disorder, Treatment, and Change: A Resource for Clinical Psychiatrists. American Journal of Psychiatry, 181(11), 958–972. https://doi.org/10.1176/appi.ajp.20231023

Ross, R. K., Inose, S., Shulman, M., Nunes, E. V., Zalla, L. C., Burlew, A. K., & Rudolph, K. E. (2024). Variation in Opioid Agonist Dosing in Clinical Trials by Race and Ethnicity. JAMA Network Open, 7(10), e2436612. https://doi.org/10.1001/jamanetworkopen.2024.36612

Hayes, C. J., Raciborski, R. A., Nowak, M., Acharya, M., Nunes, E. V., & Winhusen, T. J. (2024). Medications for opioid use disorder: Predictors of early discontinuation and reduction of overdose risk in US military veterans by medication type. Addiction. Portico. https://doi.org/10.1111/add.16659

Levin, F. R., Mariani, J. J., Pavlicova, M., Choi, C. J., Basaraba, C., Mahony, A. L., Brooks, D. J., Brezing, C. A., & Naqvi, N. (2024). Extended-Release Mixed Amphetamine Salts for Comorbid Adult Attention-Deficit/Hyperactivity Disorder and Cannabis Use Disorder: A Pilot, Randomized Double-Blind, Placebo-Controlled Trial. Journal of Attention Disorders, 28(11), 1467–1481. https://doi.org/10.1177/10870547241264675

Pusnik, A., Hartzler, B., Vjorn, O., Rutkowski, B. A., Chaple, M., Becker, S., Freese, T., Nichols, M., & Molfenter, T. (2024). Comparison of Use Rates of Telehealth Services for Substance Use Disorder During and Following COVID-19 Safety Distancing Recommendations: Two Cross-Sectional Surveys. JMIR Mental Health, 11, e52363–e52363. https://doi.org/10.2196/52363

Ross, R. K., Nunes, E. V., Olfson, M., Shulman, M., Krawczyk, N., Stuart, E. A., & Rudolph, K. E. (2024). Comparative effectiveness of extended‐release naltrexone and sublingual buprenorphine for treatment of opioid use disorder among Medicaid patients. Addiction. Portico. https://doi.org/10.1111/add.16630

Roche, A. I., Young, A., Sabaque, C., Kelpin, S. S., Sinicrope, P., Pham, C., Marsch, L. A., Campbell, A. N. C., Venner, K., Baker-DeKrey, L., Wyatt, T., WhiteHawk, S., Nord, T., Resnicow, K., Young, C., Brown, A., Bart, G., & Patten, C. (2024). Wiidookaage’win: Beta-test of a Facebook group intervention for Native women to support opioid use recovery. Journal of Substance Use and Addiction Treatment, 163, 209396. https://doi.org/10.1016/j.josat.2024.209396

Brandt, L., Anthonipillai, N. J., López-Castro, T., Melara, R., & Espinosa, A. (2022). Substance use trajectories among urban college students: associations with symptoms of stress, anxiety, and depression before and during COVID-19. Journal of American College Health, 72(6), 1717–1726. https://doi.org/10.1080/07448481.2022.2089844

Brezing, C. A., Sibai, M., Choi, C. J., Mitra, S., Mariani, J. J., Naqvi, N., Mahony, A. L., Brooks, D., Pavlicova, M., & Levin, F. R. (2023). Open-label pilot of lorcaserin (a serotonin 2C-receptor agonist) for cannabis use disorder. Journal of Substance Use, 29(4), 487–494. https://doi.org/10.1080/14659891.2023.2202760

Parchinski, K., Neirinckx, V., Frank, C., Di Paola, A., Tarfa, A., Shenoi, S., Vander Wyk, B., Roth, P., Ghantous, T., Wegman, M. K., Strong, M., Levin, F. R., Brady, K., Nunes, E., Litwin, A. H., & Springer, S. A. (2024). Missed Opportunities for Preexposure Prophylaxis Initiation in Hospitalized Persons With Opioid Use Disorder and Infectious Diseases. Open Forum Infectious Diseases, 11(7). https://doi.org/10.1093/ofid/ofae366

Ertl, M. M., Maroney, M. R., Becker, A., Paschen-Wolff, M. M., Blankenau, A., Hoffman, S., & Tross, S. (2024). Sexual and Reproductive Justice and Health Equity for LGBTQ+ Women. Journal of Lesbian Studies, 1–29. https://doi.org/10.1080/10894160.2024.2369434

(2024). Community-Based Cluster-Randomized Trial to Reduce Opioid Overdose Deaths. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2401177

Zhang, C., Slawek, D. E., Ross, J., Zolotov, Y., Castillo, F., Levin, F. R., Sohler, N. L., Minami, H., Cunningham, C. O., Starrels, J. L., & Arnsten, J. H. (2024). Factors Associated with Medical Cannabis Use After Certification: A Three-Month Longitudinal Study. Cannabis and Cannabinoid Research, 9(3), e859–e869. https://doi.org/10.1089/can.2022.0248

Cheslack-Postava, K., Cycowicz, Y. M., Rodriguez-Moreno, D. V., Amsel, L. V., Musa, G. J., Ryan, M., Bresnahan, M., Tang, H., Geronazzo-Alman, L., Bisaga, A., Wang, Z., He, X., & Hoven, C. W. (2024). Characteristics of Adolescents with and without a Family History of Substance Use Disorder from a Minority Cohort. Children, 11(6), 671. https://doi.org/10.3390/children11060671

Shulman, M., Greiner, M. G., Tafessu, H. M., Opara, O., Ohrtman, K., Potter, K., Hefner, K., Jelstrom, E., Rosenthal, R. N., Wenzel, K., Fishman, M., Rotrosen, J., Ghitza, U. E., Nunes, E. V., & Bisaga, A. (2024). Rapid Initiation of Injection Naltrexone for Opioid Use Disorder. JAMA Network Open, 7(5), e249744. https://doi.org/10.1001/jamanetworkopen.2024.9744

Jones, J. D., Arout, C. A., Luba, R., Murugesan, D., Madera, G., Gorsuch, L., Schusterman, R., & Martinez, S. (2024). The influence of drug class on reward in substance use disorders. Pharmacology Biochemistry and Behavior, 240, 173771. https://doi.org/10.1016/j.pbb.2024.173771

Shulman, M., Provost, S., Ohrtman, K., Novo, P., Meyers-Ohki, S., Van Veldhuisen, P., Oden, N., Otterstatter, M., Bailey, G. L., Liu, D., Rotrosen, J., Nunes, E. V., & Weiss, R. D. (2024). Discontinuation of medication treatment for opioid use disorder after a successful course: The discontinuation phase of the CTN-0100 (RDD) trial. Contemporary Clinical Trials, 142, 107543. https://doi.org/10.1016/j.cct.2024.107543

Chen, Q., Gopaldas, M., Castillo, F., Leckman-Westin, E., Nunes, E. V., Levin, F. R., & Finnerty, M. T. (2024). Prevalence of Opioid Use Disorder and Opioid Overdose Rates Among People With Mental Illness. Psychiatric Services. https://doi.org/10.1176/appi.ps.20230338

Glasgow, L., Douglas, C., Sprunger, J. G., Campbell, A. N. C., Chandler, R., Dasgupta, A., Holloway, J., Marks, K. R., Roberts, S. M., Martinez, L. S., Thompson, K., Weiss, R. D., Aldridge, A., Asman, K., Barbosa, C., Blevins, D., Chassler, D., Cogan, L., Fanucchi, L., … El-Bassel, N. (2024). Effect of the Communities that HEAL intervention on receipt of behavioral therapies for opioid use disorder: A cluster randomized wait-list controlled trial. Drug and Alcohol Dependence, 259, 111286. https://doi.org/10.1016/j.drugalcdep.2024.111286

Hatch, M. A., Laschober, T. C., Ertl, M. M., Paschen-Wolff, M. M., Norman, G., Wright, L., & Tross, S. (2024). Program Director Reports of COVID-19 Lockdown-Driven Service Changes in Community-Based STI Clinics and Syringe Services Programs in the Southeastern U.S. AIDS Education and Prevention, 36(2), 129–140. https://doi.org/10.1521/aeap.2024.36.2.129

Marcus, O., & Dakwar, E. (2023). Paradigm Lost: Towards an Evidence-based Ontology in Psychedelic Medicine? International Journal of Mental Health and Addiction, 22(2), 951–964. https://doi.org/10.1007/s11469-023-01157-0

Hatch, M. A., Laschober, T. C., Paschen-Wolff, M., Ertl, M. M., Nelson, C. M., Wright, L., Lancaster, C., Feaster, D. J., Forrest, D., Hankey, C., Monger, M., Fegley, J. P., Irving, R., Young, C., Rose, J., Spector, A., Dresser, L., Moran, L., Jelstrom, E., & Tross, S. (2024). PrEP for people who use opioids: A NIDA clinical trials network survey study in Southern U.S. cities where HIV incidence is high. Drug and Alcohol Dependence, 257, 111133. https://doi.org/10.1016/j.drugalcdep.2024.111133

Stopka, T. J., Babineau, D. C., Gibson, E. B., Knott, C. E., Cheng, D. M., Villani, J., Wai, J. M., Blevins, D., David, J. L., Goddard-Eckrich, D. A., Lofwall, M. R., Massatti, R., DeFiore-Hyrmer, J., Lyons, M. S., Fanucchi, L. C., Harris, D. R., Talbert, J., Hammerslag, L., Oller, D., … Walsh, S. L. (2024). Impact of the Communities That HEAL Intervention on Buprenorphine-Waivered Practitioners and Buprenorphine Prescribing. JAMA Network Open, 7(2), e240132. https://doi.org/10.1001/jamanetworkopen.2024.0132

Slavin, M. N., West, B. S., Schreiber-Gregory, D., Levin, F. R., Wingood, G., Martino, S., Tzilos Wernette, G., Black, C., & El-Bassel, N. (2024). Correlates of Unmet Need for Modern Contraception Among Reproductive-Aged Women Involved in New York City Criminal Legal Systems. Women’s Health Reports, 5(1), 132–142. https://doi.org/10.1089/whr.2023.0177

Wai, J. M., Blevins, D., Hunt, T., Gilbert, L., Campbell, A. N. C., Levin, F. R., El-Bassel, N., & Nunes, E. (2024). An Approach to Enhancing Medication Treatment for Opioid Use Disorder in the HEALing Communities Study. Psychiatric Services, 75(6), 580–588. https://doi.org/10.1176/appi.ps.20230159

Ware, O. D., Cano, M. T., Dalal Safa, M., Garza, N., Martinez, S., & Salloum, I. (2024). Availability of substance use disorder treatment in Spanish: Associations with state‐level proportions of Spanish speakers and treatment facility characteristics in the United States. The American Journal on Addictions, 33(4), 400–408. Portico. https://doi.org/10.1111/ajad.13520

Naqvi, N. H., Srivastava, A. B., Sanchez‐Peña, J., Lee, J. K., Drysdale, A. T., Mariani, J. J., Ochsner, K. N., Morgenstern, J., Patel, G. H., & Levin, F. R. (2024). Neural correlates of drinking reduction during a clinical trial of cognitive behavioral therapy for alcohol use disorder. Alcohol, Clinical and Experimental Research, 48(2), 260–272. Portico. https://doi.org/10.1111/acer.15259

Luo, S. X., Feaster, D. J., Liu, Y., Balise, R. R., Hu, M.-C., Bouzoubaa, L., Odom, G. J., Brandt, L., Pan, Y., Hser, Y.-I., VanVeldhuisen, P., Castillo, F., Calderon, A. R., Rotrosen, J., Saxon, A. J., Weiss, R. D., Wall, M., & Nunes, E. V. (2024). Individual-Level Risk Prediction of Return to Use During Opioid Use Disorder Treatment. JAMA Psychiatry, 81(1), 45. https://doi.org/10.1001/jamapsychiatry.2023.3596

Foot, C., Korthuis, P. T., Tsui, J. I., Luo, S. X., Chan, B., & Cook, R. R. (2023). Associations between stimulant use and return to illicit opioid use following initiation onto medication for opioid use disorder. Addiction, 119(1), 149–157. Portico. https://doi.org/10.1111/add.16334

French, R., Lyons, E., Schachter, A., Treston, J. A., Marshall, A., Lattimer, J., Bisaga, A., Behar, E., & Aronowitz, S. V. (2023). “Because of this rotation, this is what I want to do”: Implementation and evaluation of a telehealth opioid use disorder clinical placement for nurse practitioner students. Journal of the American Association of Nurse Practitioners, 35(12), 826–834. https://doi.org/10.1097/jxx.0000000000000949

Castillo, F., Harris, H. M., Lerman, D., Bisaga, A., Nunes, E. V., Zhang, Z., Wall, M., & Comer, S. D. (2023). Clinical Implications of the Relationship Between Naltrexone Plasma Levels and the Subjective Effects of Heroin in Humans. Journal of Addiction Medicine, 18(2), 110–114. https://doi.org/10.1097/adm.0000000000001247

Chalmé, R. L., Frankot, M. A., & Anderson, K. G. (2023). Discriminative-stimulus effects of cannabidiol oil in Sprague-Dawley rats. Behavioural Pharmacology, 35(1), 36–46. https://doi.org/10.1097/fbp.0000000000000762

Cook, R. R., Foot, C., Arah, O. A., Humphreys, K., Rudolph, K. E., Luo, S. X., Tsui, J. I., Levander, X. A., & Korthuis, P. T. (2023). Estimating the impact of stimulant use on initiation of buprenorphine and extended-release naltrexone in two clinical trials and real-world populations. Addiction Science & Clinical Practice, 18(1). https://doi.org/10.1186/s13722-023-00364-3